BridgeBio Pharma, Inc. (BBIO) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does BridgeBio Pharma, Inc. Do?
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California. BridgeBio Pharma, Inc. (BBIO) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Neil Kumar and employs approximately 400 people. With a market capitalization of $14.4B, BBIO is one of the prominent companies in the Healthcare sector.
BridgeBio Pharma, Inc. (BBIO) Stock Rating — Reduce (April 2026)
As of April 2026, BridgeBio Pharma, Inc. receives a Reduce rating with a composite score of 37.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BBIO ranks #2,043 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BridgeBio Pharma, Inc. ranks #224 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
BBIO Stock Price and 52-Week Range
BridgeBio Pharma, Inc. (BBIO) currently trades at $74.59. The stock lost $0.93 (1.2%) in the most recent trading session. The 52-week high for BBIO is $84.94, which means the stock is currently trading -12.2% from its annual peak. The 52-week low is $28.32, putting the stock 163.3% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.
Is BBIO Overvalued or Undervalued? — Valuation Analysis
BridgeBio Pharma, Inc. (BBIO) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 39.77x, compared to 1.66x for the average Healthcare stock.
At current multiples, BridgeBio Pharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
BridgeBio Pharma, Inc. Profitability — ROE, Margins, and Quality Score
BridgeBio Pharma, Inc. (BBIO) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -75.1% versus the sector average of -33.1%.
On a margin basis, BridgeBio Pharma, Inc. reports gross margins of 91.8%, compared to 71.5% for the sector. The operating margin is -1837.5% (sector: -66.1%). Net profit margin stands at -1619.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 5467.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
BBIO Debt, Balance Sheet, and Financial Health
Balance sheet data for BBIO is evaluated through our stability factor. The current ratio is 2.77x, indicating strong short-term liquidity. Total debt on the balance sheet is $2.01B. Cash and equivalents stand at $643M.
BBIO has a beta of 1.10, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for BridgeBio Pharma, Inc. is 50/100, reflecting average volatility within the normal range for its sector.
BridgeBio Pharma, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, BridgeBio Pharma, Inc. reported revenue of $351M and earnings per share (EPS) of $-3.78. Net income for the quarter was $-703M. Gross margin was 91.8%. Operating income came in at $-576M.
In FY 2025, BridgeBio Pharma, Inc. reported revenue of $502M and earnings per share (EPS) of $-3.78. Net income for the quarter was $-733M. Gross margin was 95.8%. Revenue grew 126.3% year-over-year compared to FY 2024. Operating income came in at $-523M.
In Q3 2025, BridgeBio Pharma, Inc. reported revenue of $121M and earnings per share (EPS) of $-0.95. Net income for the quarter was $-185M. Gross margin was 94.6%. Revenue grew 4318.0% year-over-year compared to Q3 2024. Operating income came in at $-145M.
In Q2 2025, BridgeBio Pharma, Inc. reported revenue of $111M and earnings per share (EPS) of $-0.95. Net income for the quarter was $-184M. Gross margin was 96.7%. Revenue grew 4999.9% year-over-year compared to Q2 2024. Operating income came in at $-134M.
Over the past 8 quarters, BridgeBio Pharma, Inc. has demonstrated a growth trajectory, with revenue expanding from $2M to $351M. Investors analyzing BBIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
BBIO Dividend Yield and Income Analysis
BridgeBio Pharma, Inc. (BBIO) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
BBIO Momentum and Technical Analysis Profile
BridgeBio Pharma, Inc. (BBIO) has a momentum factor score of 64/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
BBIO vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, BridgeBio Pharma, Inc. (BBIO) ranks #224 out of 838 stocks based on the Blank Capital composite score. This places BBIO in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing BBIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BBIO vs S&P 500 (SPY) comparison to assess how BridgeBio Pharma, Inc. stacks up against the broader market across all factor dimensions.
BBIO Next Earnings Date
No upcoming earnings date has been announced for BridgeBio Pharma, Inc. (BBIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy BBIO? — Investment Thesis Summary
The quantitative profile for BridgeBio Pharma, Inc. suggests caution. The quality score of 33/100 flags below-average profitability. The value score of 30/100 indicates premium valuation. Price momentum is positive at 64/100, suggesting the trend favors buyers.
In summary, BridgeBio Pharma, Inc. (BBIO) earns a Reduce rating with a composite score of 37.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BBIO stock.
Related Resources for BBIO Investors
Explore more research and tools: BBIO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BBIO head-to-head with peers: BBIO vs AZN, BBIO vs SLGL, BBIO vs VMD.